Literature DB >> 17698974

Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation.

Paraskevi Gaganis1, John O Miners, James S Brennan, Anthony Thomas, Kathleen M Knights.   

Abstract

There is currently little information regarding the localization of UDP-glucuronosyltransferases (UGTs) in human renal cortex and medulla, and the functional contribution of renal UGTs to drug glucuronidation remains poorly defined. Using human kidney sections and human kidney cortical microsomes (HKCM) and human kidney medullary microsomes (HKMM), we combined immunohistochemistry to investigate UGT1A and UGT2B7 expression with in vitro microsomal studies to determine the kinetics of S-naproxen acyl glucuronidation. With the exception of the glomerulus, Bowman's capsule, and renal vasculature, UGT1A proteins and UGT2B7 were expressed throughout the proximal and distal convoluted tubules, the loops of Henle, and the collecting ducts. Additionally, UGT1A and UGT2B7 expression was demonstrated in the macula densa, supporting a potential role of UGTs in regulating aldosterone. Consistent with the immunohistochemical data, S-naproxen acyl glucuronidation was catalyzed by HKCM and HKMM. Kinetic data were well described by the two-enzyme Michaelis-Menten equation. K(m) values for the high-affinity components were 34 +/- 14 microM (HKCM) and 45 +/- 14 microM (HKMM). Fluconazole inhibited the high-affinity component establishing UGT2B7 as the enzyme responsible for S-naproxen glucuronidation in cortex and medulla. The low-affinity component was relatively unaffected by fluconazole (<15% inhibition), supporting the presence of other UGTs with S-naproxen glucuronidation capacity (e.g., UGT1A6 and UGT1A9) in cortex and medulla. We postulate that the ubiquitous distribution of UGTs in mammalian kidney may buffer physiological responses to endogenous mediators, but at the same time competitive xenobiotic-endobiotic interactions may provide an explanation for the adverse renal effects of drugs, including nonsteroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17698974     DOI: 10.1124/jpet.107.128603

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.

Authors:  Katherine L Gill; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-01-24       Impact factor: 3.922

Review 2.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  AAPS J       Date:  2016-06-30       Impact factor: 4.009

3.  Quantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissues.

Authors:  Guillaume Margaillan; Michèle Rouleau; John K Fallon; Patrick Caron; Lyne Villeneuve; Véronique Turcotte; Philip C Smith; Melanie S Joy; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2015-02-03       Impact factor: 3.922

4.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Authors:  Kathleen M Knights; Shane M Spencer; John K Fallon; Nuy Chau; Philip C Smith; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

Review 5.  Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

Authors:  Kathleen M Knights; Andrew Rowland; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

6.  Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.

Authors:  Kathleen M Knights; Leanne K Winner; David J Elliot; Kushari Bowalgaha; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

7.  Application of a physiologically based pharmacokinetic model to assess propofol hepatic and renal glucuronidation in isolation: utility of in vitro and in vivo data.

Authors:  Katherine L Gill; Michael Gertz; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2013-01-09       Impact factor: 3.922

8.  The Inhibition of Hepatic and Renal Glucuronidation of p-Nitrophenol and 4-Methylumbelliferone by Oil Palm Empty Fruit Bunch Lignin and Its Main Oxidation Compounds.

Authors:  Norliyana Mohamad Salleh; Sabariah Ismail; Mohamad Nasir Mohamad Ibrahim
Journal:  Pharmacogn Mag       Date:  2017-04-07       Impact factor: 1.085

9.  Ontogeny of midazolam glucuronidation in preterm infants.

Authors:  Saskia N de Wildt; Greg L Kearns; Darryl J Murry; Gideon Koren; John N van den Anker
Journal:  Eur J Clin Pharmacol       Date:  2009-10-17       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.